Behavioral intelligence for clinical trial recruitment in oncology

The recruitment problem oncology can't outrun

Oncology trial enrollment outcomes (% of sponsored trials)

%22%7D%7D%2C%22y%22%3A%7B%22grid%22%3A%7B%22display%22%3Afalse%7D%7D%7D%7D%7D) Why oncology trials miss enrollment: top barriers reported by site coordinators

Nearly 80% of oncology clinical trials fail to meet enrollment timelines. About 20% never enroll a single patient. The consequences are not abstract. Delayed trials mean delayed therapies, and for cancer patients, delay can mean the difference between treatment and hospice.

The standard playbook for clinical trial recruitment in oncology has barely evolved in two decades: cast a wide net through EHR queries, rely on overworked site coordinators, and hope the right patients show up. It is expensive, slow, and systematically biased toward academic medical centers and their surrounding populations.

What is missing is not more data. It is better intelligence about how patients actually behave.

What behavioral intelligence means in this context

Behavioral intelligence goes beyond static eligibility criteria. It analyzes patterns in how patients interact with the healthcare system: appointment adherence, prescription refill timing, screening follow-through, provider switching, and engagement with digital health tools.

Cancer clinical trial behavioral data reveals which patients are likely to enroll, which are likely to complete a protocol, and which are at risk of dropping out before a primary endpoint is reached. This is not sentiment analysis or social media scraping. It is structured, clinically grounded signal extraction from real-world health records.

The top-ranking content on this topic focuses on behavioral science as a theoretical framework for nudging recruitment. That work matters. But theory without operational infrastructure leaves trial sponsors with frameworks they cannot act on. Behavioral intelligence requires a data foundation that is scored, validated, and consented.

Why trust scoring changes the calculus

Behavioral signals are only useful if the underlying data is reliable. A prescription refill pattern means nothing if the records are duplicated, outdated, or stripped of context. A patient's screening history is useless for cohort matching if consent status is ambiguous.

This is where SuperTruth's Data Trust Index (DTI) becomes foundational. Every health data record is scored 0 to 100 across eight dimensions: Provenance (25%), Consent (20%), Recency (15%), Quality (10%), Concordance (10%), Validation (10%), Breadth (5%), and Stability (5%).

For oncology trial cohort intelligence, Recency and Concordance are especially critical. A stage III non-small cell lung cancer diagnosis from 18 months ago, confirmed across two independent sources, is operationally different from an unverified code in a claims file. DTI separates the two before any behavioral model touches the data.

How VIOLET applies this to oncology

VIOLET, SuperTruth's oncology behavioral intelligence product, is designed specifically for this problem. It layers behavioral pattern recognition on top of trust-scored records to generate cohort intelligence that trial sponsors and CROs can act on immediately.

Rather than returning a list of patients who meet inclusion criteria on paper, VIOLET identifies candidates whose behavioral signals suggest readiness. These signals include recent treatment transitions, patterns of proactive care engagement, and geographic proximity to active trial sites, enriched by DataSpine's social determinants of health data.

The result is a recruitment funnel that is narrower at the top and wider at the bottom. Fewer contacts, higher conversion. Less wasted outreach, more enrolled patients.

Addressing the retention problem before it starts

Most conversations about clinical trial recruitment in oncology stop at enrollment. But enrollment without retention is a burning budget. Oncology trials lose 15% to 30% of participants before completion, and each dropout can cost sponsors $50,000 or more in sunk costs.

Behavioral intelligence addresses retention at the point of recruitment. By identifying patterns associated with protocol adherence (consistent appointment-keeping, stable insurance status, geographic stability), VIOLET helps sponsors select cohorts that are more likely to complete the study. ConsentOS ensures that consent governance is maintained throughout, reducing one of the most common sources of regulatory friction and patient attrition.

The data infrastructure most sponsors are missing

Sponsors and CROs often have access to large volumes of real-world data. What they lack is a trust layer underneath it. When SuperTruth worked with imaware, it standardized 105,000 diagnostic records and reduced processing time from three weeks to two hours, a 95% reduction. That engagement also uncovered a patient segment driving 20% of revenue that had been invisible in the raw data.

The same principle applies to trial recruitment. The records exist. The behavioral signals exist. But without scoring, validation, and consent governance, they cannot be used responsibly or effectively.

Moving from eligible to enrolled

Oncology patients deserve access to trials that match their biology, their behavior, and their lives. Trial sponsors deserve recruitment pipelines that are faster, more accurate, and built on data they can trust.

Behavioral intelligence, grounded in scored and consented data, is how the industry closes that gap.

Further reading: See VIOLET: behavioral signal intelligence for oncology

Further reading: See our oncology intelligence solution To explore how VIOLET and the DTI Engine can improve your oncology trial recruitment, contact Louis Simeonidis, SVP of Commercial Operations, at louis@supertruth.ai or (215) 918-4140.